This strategy has been explored in the preclinical models of solid tumors like glioblastoma (HER2 and IL13Rα2 CARs) and rhabdomyosarcoma (FGFR4 and B7-H3 CARs) and shown to result in superior durability of anti-tumor effects (8, 9). This evidence concerns the gene FGFR4 and glioblastoma.